©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2015; 21(39): 11034-11043
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11034
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11034
Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?
Daan Dierickx, Nina Cardinaels, Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium
Author contributions: Dierickx D and Cardinaels N equally contributed to this paper.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Correspondence to: Daan Dierickx, MD, Department of Hematology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. daan.dierickx@uzleuven.be
Telephone: +32-16-346880 Fax: +32-16-346881
Received: April 24, 2015
Peer-review started: April 24, 2015
First decision: June 2, 2015
Revised: June 22, 2015
Accepted: September 2, 2015
Article in press: September 2, 2015
Published online: October 21, 2015
Processing time: 177 Days and 16.7 Hours
Peer-review started: April 24, 2015
First decision: June 2, 2015
Revised: June 22, 2015
Accepted: September 2, 2015
Article in press: September 2, 2015
Published online: October 21, 2015
Processing time: 177 Days and 16.7 Hours
Core Tip
Core tip: Prevention of organ rejection following solid organ transplantation requires long term immunosuppressive therapy, leading to an increased risk of infections and malignancies. Posttransplant lymphoproliferative disorder (PTLD) comprises one of the most serious complications following transplantation with high morbidity and mortality rates. In this article we will review the different aspects on PTLD following liver transplantation.